LLC-PK1 Cell Growth Is Repressed by WT1 Inhibition of G-protein i-2 Protooncogene Transcription

Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania 19104, USA.
Journal of Biological Chemistry (Impact Factor: 4.57). 01/1996; 270(51):30760-4. DOI: 10.1074/jbc.270.51.30760
Source: PubMed


The temporal expression of the early growth response gene (EGR-1) is one molecular mechanism for both maximal activation of the G alpha i-2 gene and accelerated growth in mitotically active predifferentiated LLC-PK1 renal cells. These events are dependent on an enhancer area in the 5'-flanking region of the G alpha i-2 gene that contains an EGR-1 motif (5'-CGCCCCCGC-3'). However, acquisition of the polarized phenotype in LLC-PK1 cells is accompanied by loss of EGR-1 expression and occupancy of the EGR-1 site by nuclear binding proteins other than EGR-1. We now demonstrate that one of these binding proteins is the Wilms' tumor suppressor (WT1). Furthermore, the temporal expression of WT1 in LLC-PK1 cells acquiring the polarized phenotype represses both G alpha i-2 gene activation and growth in these cells. These findings suggest the existence of differentiation-induced pathways in LLC-PK1 cells that alternatively abrogates EGR-1 and promotes WT1 gene expression, thereby modulating a target protooncogene G alpha i-2 that is participatory for growth and differentiation in renal cells. These studies emphasize the usefulness of the LLC-PK1 renal cell as a model to elucidate normal programs of genetic differentiation in which WT1 participates.

2 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Wilms tumor remains a fascinating model for understanding how genes important in normal human embryogenesis can also contribute, in their mutant form, to cancer development in childhood. The cloning of the first Wilms tumor gene, WT1, in 1989, laid the framework for a model but also emphasized the underlying genetic complexity of this embryonal kidney cancer. Despite longstanding evidence for additional Wilms tumor gene loci, by 1997 very few of these have been cloned and none has yet been proven to be involved in Wilms tumorigenesis in man. However, the potential biological properties of these candidate genes suggest that disregulation of fetal mitogens, such as insulin-like growth factor 2, may be pivotal. Nephrogenesis is clearly sufficiently flexible to absorb many genetic errors. At present, it is unclear how often a simple two mutation model may account for Wilms tumor. Understanding how the various Wilms tumor genes interrelate, if indeed they do, awaits their identification. Piecing together these pathways may eventually lead to logical targets for therapeutic interventions.
    Critical reviews in oncogenesis 01/1997; 8(1):1-27. DOI:10.1615/CritRevOncog.v8.i1.10
  • [Show abstract] [Hide abstract]
    ABSTRACT: The protooncogene G alpha(i-2) plays a pivotal role in signaling pathways that control renal cell growth and differentiation. Mitogen-activated protein kinases (MAPKs) are potential downstream effectors for G alpha(i-2) in these pathways. In predifferentiated LLC-PK1 renal cells, the temporal maximal expression of G alpha(i-2) coincided with maximal activation of MAPK(p42/p44). By contrast, pertussis toxin treatment of these cells inhibited cell growth and reduced MAPK(p42/p44) activity by 30%. These findings reflected upstream activation of MAPK kinase (MEK1), as transient transfection of cells with a plasmid encoding a constitutively active form of MEK1 increased MAPK(p42/p44) activity and cell growth, whereas treatment with PD-098059, an inhibitor of MEK1 activity, reduced MAPK(p42/p44) activity and cell growth. Expression of a guanosinetriphosphatase (GTPase)-deficient G alpha(i-2) in these cells increased MAPK(p42/p44) activity and correspondingly reduced cell doubling time from 24 to 10 h without altering the activity of Raf-1 or c-Jun/stress-activated protein kinases (SAPKs). By contrast, expression of a GTPase-deficient G alpha(i-3) in these cells reduced both their cell doubling time by 30% and MAPK(p42/p44) activity by 60%. As the known MEKK isoforms (MEKK1, -2, and -3) can also activate SAPKs, these findings suggest the GTP-charged G alpha(i-2) subunit transduces growth signals in renal cells via activation of MAPK(p42/p44) and that such activation may be linked to pathways containing novel MEKK isoforms that preferentially activate MEKs.
    The American journal of physiology 03/1997; 272(2 Pt 2):F273-82. · 3.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: SSTR3, a somatostatin (SST) receptor, is an adenylyl cyclase (AC)-inhibiting receptor. To assign the G-protein alpha-subunit (G alpha) linked to this receptor, we created a novel reporter system which utilizes the well-established facts that the C-terminal 5 residues of G alpha are the receptor contact site and G alpha(s) stimulates all subtypes of AC. We constructed chimeric G alpha(s) the C-terminal 5 residues of which were replaced with the corresponding C-terminus of each known G alpha, and examined which chimera confers SSTR3-induced activation of AC. Cellular transfection of SSTR3 and measurement of SST-dependent AC activity through co-transfected chimeric G alpha(s) revealed that SSTR3 recognizes the C-termini of G alpha(i1/2) but not of G alpha(o) or G alpha(z), and those of G alpha(14) and G alpha(16), but not of G alpha(q) or G alpha(11). As predicted by the chimeric G alpha(s), SST-bound SSTR3 stimulated polyphosphoinositide turnover only when G alpha(16) or G alpha(14) was co-transfected. We conclude that the chimeric G alpha(s) system provides a new approach towards the assignment of G-proteins linked to a given receptor.
    FEBS Letters 05/1997; 406(1-2):165-70. DOI:10.1016/S0014-5793(97)00257-3 · 3.17 Impact Factor
Show more

Similar Publications